GlassScriptPhysician profile
Robert Rankin
NPI 1487850699
$11,213.07
in general payments reported to CMS, 2019-2025
39 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $1,454 · 2021: $3,445 · 2022: $790 · 2023: $3,286 · 2024: $236 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,495 · Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,495.00 |
| Food and Beverage | $1,339.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,194.88 | 2019-2025 | Proclaim, Axium, Eterna |
| International Rehabilitative Sciences, INC | $2,495.00 | 2023 | Rs4i Plus Sequential Stimulator |
| Nevro Corp. | $1,370.02 | 2019-2023 | Senza |
| Collegium Pharmaceutical, INC. | $458.16 | 2019-2023 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.17 | 2019-2021 | |
| Abbvie INC. | $320.48 | 2021-2023 | |
| Boston Scientific Corporation | $194.21 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Allergan, INC. | $162.87 | 2019-2021 | |
| Sentynl Therapeutics, INC. | $142.60 | 2019 | |
| Scilex Pharmaceuticals INC. | $126.84 | 2019-2020 | |
| Insightec,INC | $126.43 | 2025 | Exablate |
| Arbor Pharmaceuticals, INC. | $118.18 | 2020-2021 | |
| Daiichi Sankyo INC. | $106.46 | 2019 | |
| Averitas Pharma INC. | $101.31 | 2023 | Qutenza |
| Pfizer INC. | $92.88 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $83.66 | 2022-2023 | Mild Device Kit |
| Exeltis, USA INC. | $80.23 | 2021-2022 | |
| Amgen INC. | $72.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.06 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $58.06 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.63 | 2020 | |
| Depuy Synthes Sales INC. | $34.52 | 2019-2021 | |
| Lundbeck LLC | $33.21 | 2023 | Vyepti |
| Supreme Orthopedic Systems, LLC | $30.34 | 2023 | |
| Medtronic USA, INC. | $29.72 | 2020 | |
| Biodelivery Sciences International, INC. | $26.80 | 2021 | |
| Pacira Therapeutics, INC. | $24.28 | 2019 | |
| Globus Medical, INC. | $23.12 | 2025 | Senza |
| Medtronic, INC. | $22.78 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $20.60 | 2021 | |
| Kaleo, INC. | $19.96 | 2019 | |
| Redhill Biopharma INC. | $19.36 | 2021 | |
| Horizon Therapeutics Plc | $17.53 | 2019 | |
| Bioventus LLC | $17.10 | 2019 | |
| Shionogi INC | $16.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.83 | 2020 | |
| Lilly USA, LLC | $15.27 | 2019 | |
| Ibsa Pharma INC. | $13.89 | 2020 | |
| Zyla Life Sciences, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.